Real-World Evidence in VTE

Slides:



Advertisements
Similar presentations
Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Non-valvular Atrial Fibrillation.
Advertisements

European and US Guidelines
Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.
Preventing Thrombotic Complications in ACS: State of the Art
NOACs for Cancer-Associated Thrombosis:
Duration of Dual Antiplatelet Therapy Post-ACS: Lessons From Clinical Trials.
Atrial Fibrillation and PCI
NOACs In Long-term VTE Treatment: A State Of The Art Review
Long-Term Treatment of VTE: Case Studies
US Guidelines US Guidelines Low-risk Patients.
When Is Adding Aspirin to NOACs Worth the Risk?
Thrombosis, Cancer, and NOACs
The ABCs of AF.
NOACs in Clinical Practice: Are They All the Same?
Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.
New Strategies to Prevent CV Events After Hospital Discharge
Emergency Management of NOAC Bleeding
A New Era for NOACs:.
Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.
Anticoagulation Highlights From the American Heart Association Meeting 2017.
New Perspectives in AF and PCI: Implications for the Practicing Physician.
Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.
New Perspectives in CAD and PAD: Weighing the Latest Evidence
Global Burden of VTE. Preventing Thrombosis During and Post-Hospitalization: New Paradigms in Clinical Care.
Surveying the Safety of NOACs in the Real World
Selecting NOACs for High-Risk Patients
Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI
Are We Closer to Personalized Medicine in MS?
New Oral Anticoagulants and VTE Management
Real-World Safety of NOACs: What Do We Know Today?
VTE Treatment Conventional Approach
Applying Real-World Evidence in Atrial Fibrillation Into Clinical Care:
CV Risk Doesn't End in the Cath Lab
Antithrombotic Protection in CAD and HF
TAVR and the Risk of Thrombosis
Adherence in SPAF: Measures to Improve Care
Learning Objectives Classification of VTE Goals of VTE Treatment.
A Better Solution For Cancer Patients With VTE?
VTE in Cancer.
Essential Concepts in the Use of Immunotherapies in Bladder Cancer
Extending Treatment for Thrombosis: What’s the Right Choice?
Practical Considerations to Extend Treatment for VTE
Extraordinary Cases of VTE Prevention in Patients With Cancer
Treatment of Thromboembolic Disease The Need for Multiple Perspectives
CV Risk Doesn't End in the Cath Lab
Anticoagulation and Thrombosis Management
Identifying High-Risk AF Patients
Trials and Tribulations in VTE: How Do Real-World Data Fit In?
Long-Term Treatment of VTE: Case Studies
Factor Xa Inhibitors in PAD
CAD/PAD in Primary Care
A Time for Change for Managing Patients With VTE Who Have Cancer
Cancer-Associated Thrombosis
Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?
Managing Pulmonary Embolism Posthospital Discharge
NOAC Studies in VTE AF Studies Superior Outcomes.
Extraordinary Cases in VTE
Program Goals Background: Anticoagulation in Patients With VTE.
Factor Xa Inhibitors in Coronary Artery Disease
The ABCs of AF.
An Unmet Need.
Disease Burden of VTE Phases of VTE Treatment.
5 Good Minutes on Atrial Fibrillation-related Stroke
At the Crossroads of Coagulation
VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.
What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer
The Power of As-Treated Analyses
Antithrombotic Therapy in AF Patients Undergoing PCI
What's New in NOACs in AF?.
Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?
Presentation transcript:

Real-World Evidence in VTE

Program Goals

Overview

Khorana Risk Score Calculator

CATCH Trial

CATCH Trial: Results

CATCH Biomarker Analysis TF

VTE Recurrence Among Rivaroxaban-Treated Patients Who Continued vs Discontinued Therapy

Major Bleeding After Initial 3 Months of Therapy

Major Bleeding Among Patients With and Without Cancer Taking Rivaroxaban: A DoD Cohort Analysis

Healthcare Resource Utilization Associated With VTE Recurrence in Cancer

Healthcare Costs Associated With VTE Recurrence in Cancer

AVERT and CASSINI Trial Designs

VTE Prophylaxis

Real-World Evidence: XALIA

XALIA Results

XALIA Results (cont)

XALIA: Patients With Cancer

XALIA: Cancer Substudy Primary Outcomes

Some Studies of NOACs in Cancer

Abbreviations

Abbreviations (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.